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The number and variety of novel, molecular-targeted agents offers realistic hope for significant advances in cancer treatment. The
potential of these new treatment approaches is unquestionable, but the reality is something that only thorough clinical evaluation and
experience can reveal. Clinical experience of targeted therapies is at an early stage but it is likely that we will have an increasing
number of treatment options available to us in the near future. This manuscript explores our current understanding of molecular-
targeted therapies and considers: What approach should be used? (single vs multitarget agents); When should they be administered?
(identifying the optimal point for intervention); How should they be used? (monotherapy or combination therapy regimens); and Who
should we be giving them to? (acknowledging the need for patient selection).
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In our search for new and effective approaches to the treatment
of cancer, a wide range of processes essential to tumour growth
and development have been identified as novel targets for
anticancer therapy. The result has been the emergence of a new
generation of therapeutic agents, the molecular-targeted drugs.
Among these are many agents designed to inhibit tumour cell
proliferation, such as proteosome inhibitors, cyclin-dependent
kinase inhibitors and farnesyl transferase inhibitors. Other agents
with direct antitumour activity inhibit growth factors that play a
key role in tumour cell proliferation and survival, the most
prominent of these is epidermal growth factor (EGF). However, a
large proportion of the molecular-targeted agents currently in
development primarily affect the tumour vasculature by either
preventing vessel growth (antiangiogenic agents) or by destroying
existing blood vessels (vascular-disrupting agents). In short, an
array of novel agents is likely to become available in the clinic in
the next decade and it is important that we understand the
therapeutic potential, and limitations, of these novel approaches to
cancer treatment.
CURRENT USE OF MOLECULAR-TARGETED AGENTS
The first clinically available molecular-targeted agent was imatinib
mesylate (Glivec
s), which exemplifies a rationally designed
therapy. This agent, which inhibits BCR-ABL, platelet-derived
growth factor receptor (PDGFR) and c-KIT tyrosine kinases, has
rapidly become established as the gold standard therapy for
chronic myeloid leukaemia and gastrointestinal stromal tumours
(GIST) (Druker, 2002). To date, the other clinically available
molecular-targeted agents target one of two key growth factors
crucial for tumour growth and development, vascular endothelial
growth factor (VEGF) and EGF, as do many of the agents currently
in development.
Vascular endothelial growth factor is the most potent of
the angiogenic factors that function in tumour vascular develop-
ment (Hicklin and Ellis, 2005). The first commercially available
antiangiogenic agent, bevacizumab (Avastint), is a monoclonal
antibody (MAb) that binds to VEGF directly, thereby inhibiting
receptor binding and activation. The regulatory agency approval
of bevacizumab was based on a study of patients with colorectal
cancer (CRC) receiving bevacizumab in combination with
irinotecan/5-fluorouracil/leucovorin, which provided the first
clear demonstration of the value of inhibiting VEGF signalling to
improve patient survival over chemotherapy alone (Hurwitz et al,
2004). This agent is currently licensed for use in combination
with 5-fluorouracil-based chemotherapy for first-line treatment of
patients with metastatic carcinoma of the colon or rectum in the
USA, and for use in combination with 5-fluorouracil/leucovorin
or 5-fluorouracil/irinotecan in Europe. In contrast to bevacizumab,
the majority of the anti-VEGF inhibitors currently in development
target signalling through the VEGF receptor tyrosine kinase.
Tyrosine kinases are primary mediators of the transmission of
extracellular signals into the cell and therefore control many
crucial functions including cell differentiation, growth and
migration, depending on the signal received from the specific
receptor (Levitzki, 2002). Unlike MAbs, the tyrosine kinase
inhibitors (TKIs) will, to a lesser or greater extent, have multitarget
activity.
Epidermal growth factor binds to EGFR (HER1, erB1), inducing
receptor dimerisation and activation of receptor tyrosine kinase
activity, thereby influencing a range of key cellular functions such
as cell growth, proliferation and apoptosis (Lockhart and Berlin,
2005). The clinical value of inhibiting EGFR signalling with TKIs
has been confirmed with the EGFR TKIs gefitinib (Iressat) and
erlotinib (Tarcevat), which are approved for the treatment of
patients with locally advanced or metastatic non-small-cell lung
cancer (NSCLC) after failure of at least one prior chemotherapy
regimen. Gefitinib’s approval was based on data from two large
phase II dose-randomised trials (IDEAL 1 and 2) that showed
significant antitumour activity (Fukuoka et al, 2003; Kris et al, *Correspondence: Dr RS Herbst; E-mail: rherbst@mdanderson.org
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second- and third-line treatment in patients with advanced NSCLC
that demonstrated improved survival in these patients compared
with best supportive care alone (Shepherd et al, 2004). Further
support for the targeted inhibition of EGF activity has been seen
with cetuximab (Erbituxt), a monoclonal anti-EGFR antibody for
the treatment of EGFR-expressing, metastatic CRC. FDA approval
of cetuximab was based on a series of studies that demonstrated
the clinically significant activity of this agent (Cunningham et al,
2004).
UNDERSTANDING THE TOXICITY POTENTIAL OF
NOVEL AGENTS
Advances in cancer treatment and management mean that a
number of tumour types can be considered as chronic conditions
requiring long-term management. The safety profile of therapeutic
agents designed for chronic administration is therefore increas-
ingly important. The toxic effects of conventional chemotherapies
are a major limitation of their use and can have a significant
adverse impact on patient quality of life. The drug regimens for
cytotoxic agents are based on the need for an aggressive approach,
followed by a recovery period before the next treatment. In
contrast, the nature of the targeted agents offers the potential for
lower toxicity as their actions may have little or no effect on other
body systems. Clinical evaluation of a wide range of targeted
therapies has, however, shown us that these novel agents are not
without toxicity issues, and the benefit:risk ratio of each agent will
require careful evaluation. It is possible that the adverse events
associated with targeted therapy may be less acute as the effects
of therapy are less far-reaching than chemo- or radiotherapy. The
potential for more subtle toxicities with molecular-targeted agents
will, however, require long-term monitoring.
One of the first antiangiogenic agents to be evaluated in patients
was SU5416, an inhibitor of the VEGFR and c-KIT receptor
tyrosine kinases (Fong et al, 1999). While this early agent advanced
our understanding of the potential of this new class of drugs, its
clinical application was severely limited by poor physical and
pharmacokinetic properties (necessitating frequent parenteral
administration in a Cremophor vehicle) and a range of adverse
effects that included many cardiovascular events (Kuenen et al,
2002; Heymach et al, 2004a). The lack of demonstrable clinical
efficacy seen with this agent, as well as negative data from other
studies of novel agents, was therefore disappointing. While
bevacizumab had demonstrated activity in patients with renal,
breast and NSCLC, (Hillan et al, 2003; Yang et al, 2003; Johnson
et al, 2004) a turning point came with the results of the phase III
study of the bevacizumab/IFL combination in patients with CRC,
providing the first conclusive evidence of a survival benefit with
molecular-targeted antiangiogenic therapy over a conventional
chemotherapy regimen alone (Hurwitz et al, 2004). However, since
the launch of bevacizumab, healthcare providers have been warned
of the increased risk of arterial thromboembolic events associated
with its use. These events include transient ischaemic attacks,
myocardial infarctions and angina, some of which were fatal. In
patients with NSCLC, a study of bevacizumab in combination with
carboplatin and paclitaxel has identified squamous cell histology
as predisposing for an increased risk of bleeding and life-
threatening pulmonary haemorrhage (Johnson et al, 2004).
The range of VEGFR TKIs currently in development seem to
have varying toxicity profiles and further evaluation will elucidate
those with the most promising benefit:risk ratio. It is the role of
the phase I study to identify toxicity problems and despite the
inevitable failures at this stage many anti-VEGF agents have
demonstrated acceptable tolerability and have moved to a more
advanced stage of clinical development. PTK787, BAY 43-9006,
SU11248 and ZD6474 have generally demonstrated manageable
safety profiles and the dose-limiting toxicities tend to be manage-
able events such as gastrointestinal toxicity, fatigue and rash.
Hypertension has also been reported with some of the VEGFR
TKIs and is likely to occur as a result of VEGFR inhibition. It is
therefore interesting that some of the observed drug-related
adverse events may act as surrogate markers of target inhibition.
An example of this in another class of molecular-targeted agents
is seen with EGFR inhibition, which has been associated with the
development of rash, a common and dose-related observation in
studies of erlotinib and cetuximab (Perez-Soler, 2003). In fact,
there may be a correlation between patients who develop severe
drug-induced rash and improved survival (Perez-Soler, 2003).
CLINICAL APPLICATION OF NOVEL THERAPIES
The number and variety of novel targeted agents offers realistic
hope for significant advances in cancer treatment. The ongoing
clinical evaluation of these agents will reveal which offer the
greatest therapeutic value, but the range of target profiles and
properties poses a number of questions. Clinical experience of
molecular-targeted therapies is at an early stage, but it is likely that
we will have an increasing number of treatment options available
to us in the near future. The potential of these new treatment
approaches is unquestionable, but the reality is something that
only thorough clinical evaluation and experience will answer. In
the meantime, we can consider the ‘What, When, How and Who?’
of targeted therapies.
What?   single vs multiple targets
The molecular-targeted agents currently in development can be
described in terms of their target profile as being single- or
multiple-target agents (Table 1). However, the only agents that are
purely targeted against one receptor are the MAbs, as small
molecule ATP-competitive agents frequently have additional off-
target activities against other receptor tyrosine kinases, especially
at higher doses. To date, our clinical experience is based on agents
with specific primary targets, that is, the anti-VEGF MAbs
bevacizumab and cetuximab, and the EGFR TKIs erlotinib and
gefitinib. A number of other highly selective agents are in
development, such as IMC-1C11, an anti-VEGFR-2 MAb and TKIs
with VEGFR-specific activity (e.g. CEP-7055 and GW-786034), all
of which have demonstrated promising efficacy and safety in early
clinical studies (Posey et al, 2002; Pili et al, 2003). It could be
argued that the target specificity of these agents provides a ‘clean’
approach to therapy and enables the efficacy and tolerability to be
determined in the absence of effects caused by inhibition of other
pathways. For the antiangiogenic agents in particular, however,
this single profile may predict the need for use in combination
with other agents in order to maximise the treatment effect.
Indeed, the only licensed antiangiogenic agent, bevacizumab, has
Table 1 Activity profile of molecular-targeted agents
Single target Multiple target
Bevacizumab (anti-VEGF MAb) BAY 43-9006 (Raf-1, VEGFR-2 and -3, and
PDGFR-b)
Cetuximab (EGFR MAb) PTK787 (VEGFR-1, -2 and -3, PDGFR-b
and c-Kit )
IMC-1121b (VEGFR-2 MAb) SU11248 (VEGFR-1, -2 and -3, Flt-3,
PDGFR, c-Kit and CSF-1)
ZD6474 (VEGFR and EGFR)
AEE-788 (VEGFR, EGFR, erb)
AMG 706 (VEGFR, PDGFR, c-Kit and Ret)
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(Hurwitz et al, 2004).
Many of the newer agents inhibit more than one receptor
tyrosine kinase and these compounds may have unique inhibition
profiles. For example, ZD6474 inhibits both VEGFR and EGFR
tyrosine kinase activity, and therefore has the ability to block two
key processes in tumour development (Wedge et al, 2002). Other
agents possess different receptor tyrosine kinase inhibition
profiles, such as PTK787, an oral inhibitor of VEGFR tyrosine
kinase that also inhibits the related kinases PDGF-b receptor and
c-Kit (Wood et al, 2000; Drevs et al, 2003; George et al, 2003;
Reardon et al, 2003). BAY 43-9006 is a potent inhibitor of Raf-1
(the Ras/Raf signalling pathway being an important mediator of
tumour cell proliferation and angiogenesis), VEGFR and PDGFR
TKIs. These agents can therefore inhibit both tumour cell
proliferation and angiogenesis. Clinical evaluation of ZD6474,
PTK787 and BAY 43-9006 has been promising, with evidence of
tumour regression observed in a variety of tumour types, including
NSCLC, renal cell carcinoma, CRC, melanoma, thyroid, sarcoma
and pancreas (Minami et al, 2003; Ahmad and Eisen, 2004; Ratain
et al, 2004; Siu et al, 2004; Veronese et al, 2004; Wilhelm et al,
2004). SU11248 inhibits a still wider range of receptor tyrosine
kinases, with in vitro activity against VEGFR-1, VEGFR-2, Flt-3,
PDGFR, c-Kit and CSF-1 receptor tyrosine kinase activity (Abrams
et al, 2003a,b). The antitumour activity of this agent has been
demonstrated in a study of patients with GIST. While the efficacy
and safety profile of SU11248 has been deemed sufficient to
warrant further investigation, the incidence of adverse events has
been greater than with imatinib, highlighting the potential for
multitargeted approaches to be associated with a comparatively
high toxicity profile.
Agents that can target several pathways in tumour growth are
highly attractive, potentially offering the benefits of combined
therapy within a single agent. Such combined effects may,
however, make it difficult to demonstrate the relative benefits of
targeting each pathway and the possibility of additive toxicity will
require thorough evaluation.
When? – identifying the optimal point of intervention
As with all anticancer strategies, detecting and treating tumours
at the earliest possible stage is likely to result in the best outcome
for the patient. This may be of particular importance for
the antiangiogenic agents, where prevention of tumour develop-
ment, rather than frank regression, is the anticipated effect.
Early intervention with an antiangiogenic agent could, in theory,
prevent metastatic spread and while clinical demonstration
of this effect is likely to prove difficult, preclinical evidence is
compelling (Drevs et al, 2002; Wu et al, 2004). An additional
consideration is the knowledge that VEGF is a key driver
of angiogenesis early in tumour development, but a range of
other proangiogenic factors, such as bFGF and PDGF, are likely
to contribute to vascular development at later stages (Relf et al,
1997; Pavlakovic et al, 2001; Kerbel, 2004). Patients with later
stage disease may benefit from intervention with vascular-
disrupting agents, which function by exploiting key differences
between tumour and normal blood vessels to selectively destroy
the existing tumour vasculature. Preclinical evaluation of
the vascular-disrupting agent ZD6126 has shown efficacy in a
range of tumour sizes, but particularly in larger tumours (Siemann
et al, 2002).
The use of antiangiogenic agents in the adjuvant setting is
another area of great potential. Surgical removal of tumours can
result in the development of previously dormant metastases due to
the antiangiogenic effects exerted by the dominant tumour
(Holmgren et al, 1995). Further evaluation of the benefits of
administering antiangiogenic therapy prior to surgery, or even
chemotherapy, would therefore be warranted.
How?   monotherapy or combination regimens
It is likely that the nature of the target inhibition will largely dictate
whether agents will function effectively as monotherapy or whether
combined therapeutic regimens will be required. Of the currently
available agents, the EGFR TKIs have proved effective as
monotherapy, whereas bevacizumab has demonstrated a survival
benefit only in combination regimens (Hurwitz et al, 2004). This is
likely to be due to the mechanism of action of the EGFR inhibitors,
which target the tumour cells directly, whereas VEGF inhibition
can be anticipated to elicit a cytostatic effect and therefore
combination with conventional approaches may be required in
order to eradicate the tumour. Currently available agents and
developmental therapies alike are therefore being investigated in a
wide range of combination regimens, sometimes to the exclusion
of monotherapy studies (Table 2). PTK787 and early studies of
ZD6474 have, however, shown evidence of efficacy as monotherapy
(Minami et al, 2003; Morgan et al, 2003). In addition, a phase III
study of SU11248 monotherapy in patients with imatinib-resistant/
imatinib-intolerant GIST has recently been halted ahead of
schedule as interim analysis clearly demonstrated the efficacy
benefits of this approach. While it is evident that targeted agents
can prove effective as monotherapy, the question is whether this
efficacy can be improved upon with combination regimens.
To date, the most successful use of the antiangiogenic agents has
been in combination with certain conventional chemotherapies
(Hurwitz et al, 2004; Steward et al, 2004). It is possible that
combined use may enable the constituent agents to be used at
lower doses, but the potential drug–drug interactions and altered
pharmacokinetic and biological effects of drug combinations
require careful evaluation. An additional benefit of combination
therapy is the observation that antiangiogenic therapy may result
in a degree of normalization of blood vessels. (Jain, 2001; Willett
et al, 2004). As tumour blood vessels are structurally and
functionally abnormal, blood flow throughout the tumour is
variable and areas of hypoxia are common. Vascular endothelial
growth factor inhibitors have been shown to decrease interstitial
pressure and increase oxygen tension, and this may assist the
delivery of cytotoxic agents (Jain, 2001). In addition to comple-
menting chemotherapy regimens, it is possible that targeted agents
could enhance the therapeutic efficacy of radiation therapy as
VEGF levels and tumour cell EGFR expression have been shown to
increase following exposure to ionising radiation (Akimoto et al,
1999; Dent et al, 1999; Gorski et al, 1999). There has been little
clinical evaluation of this application to date, but a wealth of
preclinical studies have provided convincing evidence for this
approach (Gorski et al, 1998; Mauceri et al, 1998; Gustafson et al,
2004; Siemann and Shi, 2004; Williams et al, 2004).
The specific benefits of the combined use of targeted agents is
being investigated in a number of studies evaluating the combined
use of these agents. A dual approach to targeting tumour cell
proliferation directly by inhibiting EGF activity, plus tumour
vascularization by inhibiting VEGF activity is attractive, and
studies of bevacizumab plus the EGFR TKI erlotinib have shown
positive results in a second/third-line study of patients with
NSCLC of non-squamous cell histology (Herbst et al, 2005). In this
study, partial responses were seen in 20% of patients, and stable
disease in 65% (Herbst et al, 2005). Ongoing clinical evaluation of
ZD6474 will elucidate the benefit of a single-agent approach to
VEGFR and EGFR inhibition.
The results of the ongoing studies of single-agent therapy with
multitargeted drugs and the various combination regimens
currently under investigation will hopefully clarify the differential
benefits of using multitargeted drugs vs combined use of more
selective agents. In particular, the tolerability issues associated
with these approaches will require careful evaluation in order to
demonstrate whether it may be safer to use a combination of
highly targeted agents, or one multitargeted drug.
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Heterogeneity is manifest at a number of levels in human cancer;
genetically, at the cellular level, zonally (within a tumour deposit),
between tumour deposits, and between patients. An awareness and
understanding of this heterogeneity is key to the development of
tailored biological therapies, and could be greatly assisted by the
development of better, more predictive animal models. The goal of
Table 2 Clinical experience of combination regimens
Phase of





Complete. The addition of bevacizumab to
fluorouracil-based combination chemotherapy
results in statistically significant and clinically
meaningful improvement in survival (Hurwitz
et al, 2004)
II Bevacizumab Carboplatin/paclitaxel Advanced/recurrent NSCLC
(n¼99)
Complete. Inclusion of bevacizumab resulted in
a higher response rate compared with the
control therapy (31.5 vs 18.8%), a longer
median time to progression (7.4 vs 4.2 months)
and a trend towards increased survival (17.7 vs
14.9 months) (Johnson et al, 2004)
I/II PTK787 FOLFOX-4 Metastatic CRC (n¼35) Complete. Combined treatment was well
tolerated at doses p1250mgday
 1; adverse
events at 1250mgday
 1 included grade 3
ataxia, thrombocytopenia and dizziness, and
grade 4 neutropenia. Grade 3 expressive
dysphasia and intermittent dizziness were dose
limiting at 1500mgday
 1. Best response data
for 28 evaluable patients to date show one CR,
14 PR, and nine stable disease . Estimated
median overall survival for 35 patients is 16.6
months (Steward et al, 2004)








CONFIRM-1: analysis of progression-free
survival (primary end point) showed no
statistically significant improvement over
FOLFOX-4 alone (unpublished data).
Assessment of overall survival (secondary
endpoint) ongoing
CONFIRM-2: ongoing
III Bevacizumab Carboplatin/paclitaxel Advanced/recurrent NSCLC
(first-line) n¼878
Complete. Analysis has demonstrated a survival
benefit with bevacizumab/carboplatin/paclitaxel
of 12.5 vs 10.2 months with chemotherapy
alone (unpublished data)
II ZD6474 Docetaxel Locally advanced or metastatic
NSCLC after failure of first- line
platinum-based chemotherapy
n¼4200
Ongoing. Data from safety run-in phase have
shown good tolerability with this combination
(Heymach et al, 2004b)
II ZD6474 Carboplatin/paclitaxel First-line NSCLC (n¼4200) Ongoing. Preliminary data from the safety run-
in phase show that the combination is generally
well tolerated (Johnson et al, 2005)
II Bevacizumab+erlotinib Docetaxel (alone
or+bevacizumab)
Refractory NSCLC (n¼4180) Ongoing




Ongoing. Interim data show good tolerability
and promising efficacy (Reardon et al, 2004)
I/II Bevacizumab+erlotinib n/a Stage IIIB/IV or recurrent
NSCLC (n¼40)
Complete. Eight partial responses (20%, CI
7.6 32.4%) and 26 patients with SD (65%, CI
50.2 79.8%). The median survival of 34
patients treated in the phase II part of the study
was 12.6 months, with 52% of patients alive at 1
year (Sandler et al, 2004)
I Bevacizumab+BAY 43-9006 n/a Various (n¼38) Ongoing
CR¼complete response; SD¼stable disease; PR¼partial response; NSCLC¼non-small-cell lung cancer; CRC¼colorectal cancer; n/a¼not applicable.
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cells, which accounts not only for its widespread application to
all tumour types but also for its significant associated toxicity.
Targeted therapies, by definition, act in a far more specific
manner, inhibiting biological pathways and processes that are
selectively dysregulated in tumours, thereby avoiding many of the
tolerability disadvantages of conventional chemotherapy. As a
result, however, it is likely that a ‘one size fits all’ approach cannot
be adopted with the novel agents, and that a degree of patient
selection may be required to identify the patients who are likely to
benefit most from treatment.
The successes and failures of clinical studies to date highlight the
need to identify specific patient types for treatment with the various
targeted therapeutic approaches, and a great deal of additional
investigation is required before we can claim to understand and
optimise treatment. For example, despite the excellent data
reported with bevacizumab plus chemotherapy in the first-line
CRC study, investigation of this agent as a third-line therapy in
combination with capecitabine in patients with metastatic breast
cancer has shown evidence of activity (as seen by a significant
increase in response rates), but no significant improvement in
survival (Miller et al, 2005). Such evidence of biological activity that
fails to translate into an overall survival benefit could be considered
further evidence of the need for patient characterisation; it is likely
that while specific approaches may be generally more effective in
certain tumour types, subgroups of patients that demonstrate a
survival benefit could be identified in a range of tumour types.
Although the activity of antiangiogenic agents should theoreti-
cally apply to all solid tumours, there appear to be key differences
between patient populations. One hypothesis is that although early-
stage tumours may rely on VEGF as the principal proangiogenic
factor, angiogenesis in late-stage disease may be governed by a
range of proangiogenic factors and there may be some redundancy
of VEGF (Relf et al, 1997; Pavlakovic et al, 2001; Kerbel, 2004). It is
therefore possible that VEGF is a less significant factor in late-stage,
treatment-refractory breast cancer than early-stage breast cancer
or other solid tumours. It is also possible that tumour types that
express high levels of VEGF and its associated receptors may be
particularly susceptible to antiangiogenic therapy. Microvessel
density appears to be an important prognostic marker but the
correlation with predicting response to antiangiogenic therapy is
not so clear. For example, renal tumours are highly vascularised
and would be expected to be particularly sensitive to antiangio-
geneic agents, whereas other, less vascularised, tumour types may
be less susceptible. It cannot, however, be presumed that a poorly
vascularised tumour will be less susceptible to antiangiogenic
therapy as it is well established that neovascularisation must
take place for tumours to grow beyond a certain size. Indeed, there
is some evidence to suggest that lower vascularity increases the
response to antiangiogenic therapy (Beecken et al, 2001).
In patients with NSCLC, a response to EGFR TKI therapy is
difficult to predict, but it is known that response does not appear
to correlate with the degree of EGFR expression (Bailey et al, 2005).
Mutations in the tyrosine kinase domain of the EGFR have been
correlated with clinical responsiveness to gefitinib (Lynch et al,
2004; Han et al, 2005). Such mutations were seen to be more
frequent in adenocarcinomas, in women and in Japanese patients
(Lynch et al, 2004; Paez et al, 2004). Our knowledge of specific
mutations that may predispose response to other agents is,
however, formative and further evaluation is required. Recent
phase III evaluation of gefitinib (IRESSA Survival Evaluation in
Lung cancer, ISEL) showed that the increase in overall survival of
treated patients was not statistically significantly greater than the
placebo arm. However, in patients of Oriental origin and in
patients who have never smoked, the data suggested a statistically
significant difference.
Additional evidence of the need for patient screening has come
from studies of bevacizumab in patients with NSCLC. While the
tolerability profile of this agent is generally good, multivariate
analysis has identified patients with squamous cell histology as
being at higher risk of bleeding and pulmonary haemorrhage
(Johnson et al, 2004). This adverse event has not been notable in
studies of bevacizumab in other tumour types.
CONCLUSIONS
As the clinical experience with novel anticancer agents expands,
we will be faced with increasingly complex treatment decisions to
accompany the increase in available treatment options. It will be
important to establish how these treatments can add to, or replace,
conventional cytotoxic therapy and improve on patient outcomes
from both an efficacy and safety or quality of life aspect. It will also
be important to understand which patients benefit most from the
numerous options, so that the treatment strategy can be tailored to
the individual patient and meet their needs.
The ultimate goal of cancer research has always been, and
remains, to find a cure. A more realistic interim goal for patients
with metastatic disease may, however, be to adopt a ‘regulatory
model’ of cancer, which aims to control tumour burden and limit
metastasis, thereby achieving a ‘functional cure’, rather than
eradicating all tumour cells (Schipper et al, 1995). In this way,
patients could live with cancer as a chronic disease that can be
effectively managed with similar efficacy to diabetes and heart
disease. The molecular-targeted agents could prove instrumental in
achieving this goal by providing different methods of slowing or
stopping tumour growth in a chronic treatment setting. Continued
research and clinical evaluation will serve to expand our under-
standing and improve our ability to provide optimal, tailored
therapeutic strategies with this new generation of anticancer agents.
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